Rosenstrauch Doreen, Poglajen Gregor, Zidar Nina, Gregoric Igor D
Heart Failure Research Laboratory, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
Tex Heart Inst J. 2005;32(3):339-47.
As the prevalence and incidence of ischemic heart disease continue to increase, so does interest in ischemic heart failure management. Limitations of current therapies have led to research aimed at regenerating and repairing ischemically damaged myocardium through stem-cell therapy. Cell types being evaluated include embryonic stem cells, fetal and neonatal cardiomyocytes, skeletal myoblasts, bone marrow stem cells, peripheral blood CD34+ cells, endothelial progenitor cells, cardiac progenitor cells, and fibroblasts. Preclinical animal studies and promising early results of clinical trials now under way suggest that stem-cell therapy may soon become an important new tool in heart failure management.
随着缺血性心脏病的患病率和发病率持续上升,人们对缺血性心力衰竭管理的兴趣也在增加。当前疗法的局限性促使人们开展研究,旨在通过干细胞疗法使缺血受损的心肌再生和修复。正在评估的细胞类型包括胚胎干细胞、胎儿和新生儿心肌细胞、骨骼肌成肌细胞、骨髓干细胞、外周血CD34+细胞、内皮祖细胞、心脏祖细胞和成纤维细胞。目前正在进行的临床前动物研究和有前景的早期临床试验结果表明,干细胞疗法可能很快成为心力衰竭管理中的一项重要新工具。